他克莫司治疗膜性肾病的Meta分析  

Tacrolimus in treatment of membranous nephropathy by Meta analysis

作　　者：张婕[1] 何旭[2] 张黎雯[2] 徐敏[2] 李静[2] 刘光陵[2] 

机构地区：[1]南京大学医院院临床学院 [2]南京军区南京总医院儿科,南京210002

出　　处：《肾脏病与透析肾移植杂志》2011年第1期23-28,共6页Chinese Journal of Nephrology,Dialysis & Transplantation

摘　　要：目的：用Meta分析方法评价他克莫司治疗膜性肾病（MN）的疗效和安全性. 方法：运用Cochrane图书馆、PubMed,Medline database和中国期刊全文数据库（CNKI）、中文科技期刊全文数据库（VIP）检索他克莫司治疗MN的随机对照临床试验（randomized controlled clinical trials,RCT）,2010年9月25日检索文献截止,对符合标准的文献进行质量评价和Meta分析. 结果：收集国内外5个随机对照研究,纳入188例患者.Meta分析结果显示,他克莫司治疗组与对照组相比,治疗MN的完全缓解（RR=2.16 95%,CI 1.32～3.55）及总缓解（RR=1.59 95%,CI 1.27～2.01）有显著的统计学意义,经对症处理后主要不良反应都能恢复. 结论：目前证据表明,他克莫司治疗MN与传统的治疗方案相比疗效更好.Objective：To assess the effect and safety of tacrolimus in treatment of membranous nephropathy by Meta analysis. Methodology：The data of Coehrane Library, PubMed, CNKI and VIP until September 25, 2010 were retrieved to search the studies about the randomized controlled clinical trials （RCTs） in the treatment of membranous nephropathy by tacrolimus. Standard studies were used by quality evaluation and Meta analysis. The qualities of included articles were assessed and then a meta-analysis was conducted. Results： Five RCTs studies in which included 188 patients at home and abroad were collected. Meta analysis showed that compared with the control group, tacrolimus was more effective in complete remissions （RR = 2. 16 95% , CI 1.32 -3.55 ） and total remission （RR = 1.59 95% , CI 1.27 2.01 ）. Adverse effect could be recovered by symptomatic treatment. Conclusion：The current limited evidence suggests that tacrolimus is more effective than traditional protocols in treatment of membranous nephropathy.

关 键 词：他克莫司 FK506 META分析 膜性肾病 

分 类 号：R692.3[医药卫生—泌尿科学]